#AntibodyDiscovery
LightNews LightNews
milaboratories.bsky.social
MiXCR powered BCR extraction in this study, and with Platforma you can now go further—model structure, predict binding affinity, and rank top antibody leads by developability.

Learn more here: platforma.bio/antibody-dis...

#antibody #antibodydiscovery #antibodyengineering
November 20, 2025 at 12:23 PM
ipiproteins.bsky.social
Come work with us! IPI is seeking a #postdoctoralfellow to join us and apply our #antibodydiscovery platforms to cutting-edge questions in #cellsurface #proteinresearch and #antibodyengineering. It could be you!

Learn how to apply today: buff.ly/f2cLV4D
November 19, 2025 at 8:30 PM
ipiproteins.bsky.social
“What drives my research is the real-world impact that we make,” says Swethika Balasankar, a research associate on IPI’s #AntibodyDiscovery team.

Find out more about how IPI is shaping #proteinscience 🔬
buff.ly/Fd2qroB
November 6, 2025 at 4:45 PM
genewiz.bsky.social
Are you attending #PEGSEurope 2025 next week? Meet us at booth #249 to chat with our team, design a wizard trading card, and join contests for a chance to win exclusive prizes! Join our presentations for insights to empower your research: hubs.ly/Q03RsttC0

#PEGS2025 #PEGSummit #AntibodyDiscovery
November 6, 2025 at 4:06 PM
ipiproteins.bsky.social
Hello from the #PRIMESummit @cytiva.bsky.social! What an incredible opportunity to get into the details of #proteinpurification, #labautomation and #antibodydiscovery, right here in Boston!

Learn more about the IPI platform: buff.ly/zNIF9vw
October 17, 2025 at 3:30 PM
ipiproteins.bsky.social
It’s conference season! We're just back from AXON2025 & Discovery on Target where we: shared progress on antibodies to 50+ neuronal targets, discussed strategies for #membraneprotein and #GPCR discovery & met determined researchers in #braindevelopment #synapticplasticity #antibodydiscovery & more.
September 26, 2025 at 5:04 PM
imprintlabs.bsky.social
A huge thank you to @mofollp.bsky.social and West End Labs for bringing together leaders across science, technology and business to push the boundaries of what’s possible in NYC!

#MoForum #MachineLearning #Immunology #AntibodyDiscovery #AIForScience
September 25, 2025 at 4:01 PM
imprintlabs.bsky.social
Our CEO & Co-Founder @beckbrachman.bsky.social spoke at @mofollp.bsky.social #MoForum in NYC on how AI/ML is reshaping immunology and the opportunities ahead for life sciences — alongside amazing innovators! 🧠

#MachineLearning #Immunology #AIForScience #AntibodyDiscovery
September 25, 2025 at 4:01 PM
ipiproteins.bsky.social
Research at IPI directly impacts discovery — and this is a big part of what motivates IPI scientist Rebecca Hershman in the lab.

#proteinscience #proteomics #antibodydiscovery #proteininnovation 💪⚖️

buff.ly/HLvHdPR
September 24, 2025 at 9:05 PM
lightcastbio.bsky.social
Antibody-based immunotherapies can target disease with high precision — but #AntibodyDiscovery workflows are slow & costly.

Using streamlined functional analysis earlier in the discovery process can help deliver promising therapies quicker, writes our own Jonathan Didier.

go.lightcast.bio/47R6ZoF
Why antibody discovery needs to focus on function
Early functional testing could transform the future of antibody-based therapies — here’s how.
www.drugdiscoverynews.com
September 22, 2025 at 3:23 PM
imprintlabs.bsky.social
At IMPRINT, this mindset drives our push for robust AI-based mapping of adaptive immunity.

News & Views feature: doi.org/10.1038/s422...

#MachineLearning #Immunology #AntibodyDiscovery #AIForScience
The importance of negative training data for robust antibody binding prediction - Nature Machine Intelligence
Thoughtfully designed negative training datasets may hold the key to more robust machine learning models. Ursu et al. reveal how negative training data composition shapes antibody prediction models an...
doi.org
September 18, 2025 at 3:02 PM
lightcastbio.bsky.social
#AntibodyDiscovery is at a turning point: traditional methods focused on binding rather than function are no longer sufficient.

By leveraging droplet #microfluidics our Envisia platform enables deeper analysis of cellular functions.

Learn more at our presentation @ the #FestivalofBiologics!
September 16, 2025 at 1:01 PM
ipiproteins.bsky.social
What drives protein science at IPI? We asked our team — and the answers totally wowed us!

We’re featuring their responses this fall, starting with IPI research associate Robert May. Come along with us on the ride!

#whatdrivesmyscience #proteinscience #bioscience #antibodydiscovery #research
September 3, 2025 at 5:45 PM
4040rec.bsky.social
#KlingBio #Sanofi #antibodydiscovery #vaccines #Bcellplatform #KlingSelect #monoclonalantibodies #humanviralpathogen #antiviraltherapies #vaccinedesign #Bcellimmortalisationandscreeningplatform #RSV #COVID19 #influenza #KlingSelectplatform
pharmatimes.com/news/kling-b...
Kling Bio partners with Sanofi to accelerate antibody discovery - PharmaTimes
Collaboration aims to advance next-generation therapeutics and vaccines
pharmatimes.com
August 28, 2025 at 12:19 PM
lightcastbio.bsky.social
Our Envisia platform takes a function-focused approach to #AntibodyDiscovery, streamlining the discovery workflow with:

1️⃣ Real-time functional insights
2️⃣ Multi-assay screening
3️⃣ Faster hit identification & single-cell recovery
4️⃣ oEWOD technology to eliminate crosstalk

go.lightcast.bio/47w2EH3
Four ways Envisia is changing the game in antibody discovery
By integrating single-cell analysis, multi-functional assays, and robust cell recovery into one seamless system, Lightcast empowers researchers to shift from a binding-first approach to a function-focused paradigm. Workflows on the Envisia platform has the potential to enhance lead quality, reduce attrition rates, and accelerate the discovery of antibodies with real therapeutic potential.
go.lightcast.bio
August 14, 2025 at 12:06 PM
ipiproteins.bsky.social
What can we extract from our #antibody selection data? Certainly more — with #AI on our side. Read how IPI and collaborators @harvardmed.bsky.social applied #machinelearning and #artificialintelligence to streamline #antibodydiscovery for cell surface #antigens.
proteininnovation.org/2025/05/mach...
Machining antibodies at IPI
Very little these days escapes the reach of machine learning (ML) and, more broadly, artificial intelligence (AI). Antibodies have caught the AI train, as
proteininnovation.org
July 3, 2025 at 5:20 PM
vectorbuilder.bsky.social
🎉 Service Launch: Phage Display Library Construction 🎉
We’re excited to introduce our Phage Display Library Construction service, designed to accelerate your antibody discovery, vaccine development, and protein interaction studies. 👉 Visit our page: rb.gy/erargh
#PhageDisplay #AntibodyDiscovery
Phage Display Library Construction Process Steps
June 19, 2025 at 8:01 PM
lightcastbio.bsky.social
(3/3) The result? Accurate, functional antibody recovery ready for downstream sequencing and analysis.

Find out how Envisia can help your research in #DrugDiscovery, #AntibodyDiscovery and more: go.lightcast.bio/3FZ0zby
Envisia Platform | Integrated Benchtop System for Functional Discovery
Explore how the Envisia Platform combines a benchtop instrument, cartridge, and software to deliver end-to-end control for single-cell functional analysis. Designed to streamline setup, scale experime...
go.lightcast.bio
June 19, 2025 at 1:18 PM
lightcastbio.bsky.social
Still relying on binding-focused approaches in #AntibodyDiscovery? You could be missing your best functional candidates. Envisia, our next-generation, single-cell platform, was designed to prioritise cellular & antibody functionality from the very start.

go.lightcast.bio/4k0KyQa

#ScienceSky 🧪
Four ways Envisia is changing the game in antibody discovery
By integrating single-cell analysis, multi-functional assays, and robust cell recovery into one seamless system, Lightcast empowers researchers to shift from a binding-first approach to a function-foc...
www.lightcast.bio
June 19, 2025 at 10:28 AM
ipiproteins.bsky.social
First yeast display course = complete ✅ We spent an impactful week exploring #yeastdisplay (library construction to FACS to NGS prep) with a curious, focused & thoughtful group.
Stay tuned—we’re just getting started! mailchi.mp/proteininnov...
#antibodydiscovery #proteinengineering
June 13, 2025 at 10:13 PM
enginyapici.bsky.social
Just wrote about a platform that pulled out 𝟱 𝘀𝘂𝗯-𝗻𝗮𝗻𝗼𝗺𝗼𝗹𝗮𝗿 antibodies in 3 weeks. From plasma cells, not display libraries.

Naturally paired, functionally diverse, and validated early (blockers, agonists, bins).

medium.com/@enginyapici...

#AntibodyDiscovery #DrugDiscovery #Microfluidics #Biotech
Why the Next Great Antibody May Come from a Droplet, Not a Mouse Spleen
How a droplet-based system found sub-nanomolar antibodies in weeks, not months
medium.com
June 13, 2025 at 7:36 AM
lightcastbio.bsky.social
How can our benchtop Envisia platform accelerate #AntibodyDiscovery by bringing key cellular functions — including cytokine secretion, internalisation, and serial killing — into focus? Watch the video to learn more.

#ScienceSky 🧪 #AcademicSky #Microfluidics

www.youtube.com/watch?v=YctY...
Lightcast: The functional readouts guiding antibody discovery
YouTube video by Lightcast
www.youtube.com
June 11, 2025 at 12:14 PM
ipiproteins.bsky.social
Our #yeastdisplay for #antibodydiscovery course is off to a great start here on the Emmanuel College campus, with talks from IPI senior platform director André Teixeira, IPI scientist Deepash Kothiwal and Angela Reslow of Miltenyi Biotec yesterday! More learning to come!
June 10, 2025 at 1:11 PM
enginyapici.bsky.social
65 designs. Single shot. 16 recovered binding to XBB.1.5.

No iterative wet-lab cycles. No massive screens.

They solve three big problems in one shot: escape recovery, developability, diversity.

I broke it down here:
medium.com/@enginyapici...

#AntibodyEngieering #Biotech #AntibodyDiscovery #AI
Doing It All: A Rare Triple Play in Computational Antibody Design
How one team tackled escape mutations, developability, and diversity, with just 65 designs
medium.com
June 10, 2025 at 6:07 AM
lightcastbio.bsky.social
With the Envisia platform, you can move beyond binding to perform key biochemical and cellular assays like antibody blocking, internalisation, and cytotoxicity — all before a candidate ever leaves the platform.

Read our latest white paper: go.lightcast.bio/43HuFrR

#ScienceSky 🧪 #AntibodyDiscovery
June 3, 2025 at 1:08 PM